August 29th 2025
The 6-month progression-free survival rate for the combination therapy was 52.2%.
The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation
Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care
Kentucky's New Governor Could Change the Terms of Medicaid Expansion
Dr Lee Newcomer on Value Calculators and New Immuno-Oncology Agents
Ted Okon Outlines the Purpose of COA's Payer Exchange Summit